Alvogen launches Copaxone generic

Pharmaceutical company Alvogen has launched the first generic version of Copaxone (glatiramer acetate) in Europe under the name Remurel.

Remurel is a treatment drug for multiple sclerosis (MS) and will be launched throughout all central and eastern European countries from September 2016 onwards.

Hacho Hatchikian, executive vice president at Alvogen in the CEE region, said: “This product represents an important milestone in our growing portfolio in the region.”

He added: “It is also a landmark for Alvogen and MS patients throughout the CEE region, who will finally have access to an affordable high quality treatment for this chronic and neurodegenerative disease.”

Teva manufactures the Copaxone drug.